Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/22722
Full metadata record
DC FieldValueLanguage
dc.contributor.authorIoannidis, P.en
dc.contributor.authorMahaira, L.en
dc.contributor.authorPapadopoulou, A.en
dc.contributor.authorTeixeira, M. R.en
dc.contributor.authorHeim, S.en
dc.contributor.authorAndersen, J. A.en
dc.contributor.authorEvangelou, E.en
dc.contributor.authorDafni, U.en
dc.contributor.authorPandis, N.en
dc.contributor.authorTrangas, T.en
dc.date.accessioned2015-11-24T19:26:25Z-
dc.date.available2015-11-24T19:26:25Z-
dc.identifier.issn0250-7005-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22722-
dc.rightsDefault Licence-
dc.subjectAnimalsen
dc.subjectAntigens, Neoplasm/biosynthesis/genetics/*physiologyen
dc.subjectGene Expression Regulation, Developmentalen
dc.subjectHumansen
dc.subjectNeoplasms/genetics/metabolismen
dc.subjectProto-Oncogene Proteins c-myc/biosynthesis/*geneticsen
dc.subjectRNA, Messenger/genetics/*metabolismen
dc.subjectRNA-Binding Proteins/biosynthesis/genetics/*physiologyen
dc.titleCRD-BP: a c-Myc mRNA stabilizing protein with an oncofetal pattern of expressionen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/12894594-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2003-
heal.abstractThe Coding Region Determinant-Binding Protein (CRD-BP) is an RRM and KH-domain-containing protein that recognizes specifically at least three RNAs. It binds to one of the two c-myc mRNA instability elements, to the 5'Un Translated Region (UTR) of the leader 3 IGF-II mRNA and to the oncofetal H19 RNA. CRD-BP has been assigned a role in stabilizing c-myc mRNA by preventing its endonucleolytic cleavage and in repressing the translation of the leader 3 IGF-II mRNA, the major embryonic species of this message. CRD-BP is normally expressed only in fetal tissues. However, its expression is detected in primary tumors and transformed cell lines of different origins. The vast majority of colon (80%) and breast (60%) tumors and sarcomas (73%) express CRD-BP whereas in other tumor types, for example prostate carcinomas, its expression is rare. CRD-BP expression has also been detected in benign tumors such as breast fibroadenomas, meningiomas and other benign mesenchymal tumors, implying a role for this gene in abnormal cell proliferation. In breast carcinomas, CRD-BP expression and or gene copy number gains in the region encompassing the c-myc locus were detected in approximately 75% of tumors, implying that the deregulated expression of c-myc may be more widespread than previously believed. Infiltrated lymph nodes, corresponding to CRD-BP-positive primary tumors, were also found positive indicating that monitoring for CRD-BP could prove useful for the detection and monitoring of disseminated disease.en
heal.journalNameAnticancer Researchen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons